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Abstract
Despite the importance of the tumor microenvironment in regulating tumor progres-
sion, few in vitro models have been developed to understand the effects of non-
neoplastic cells and extracellular matrix (ECM) on drug resistance in glioblastoma 
(GBM) cells. Using CellTrace-labeled human GBM and microglial (MG) cells, we 
established a 2D co-culture including various ratios of the two cell types. Viability, 
proliferation, migration, and drug response assays were carried out to assess the role 
of MG. A 3D model was then established using a hyaluronic acid-gelatin hydrogel 
to culture a mixture of GBM and MG and evaluate drug resistance. A contact co-
culture of fluorescently labeled GBM and MG demonstrated that MG cells modestly 
promoted tumor cell proliferation (17%-30% increase) and greater migration of GBM 
cells (>1.5-fold increase). Notably, the presence of MG elicited drug resistance even 
when in a low ratio (10%-20%) relative to co-cultured tumor cells. The protective 
effect of MG on GBM was greater in the 3D model (>100% survival of GBM when 
challenged with cytotoxics). This new 3D human model demonstrated the influence 
of non-neoplastic cells and matrix on chemoresistance of GBM cells to three agents 
with different mechanisms of action suggesting that such sophisticated in vitro ap-
proaches may facilitate improved preclinical testing.
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1 |  INTRODUCTION
Glioblastoma multiforme (GBM), grade IV glioma, is the 
most common and malignant form of primary brain cancer 
accounting for nearly 45% of all gliomas.1 Although the addi-
tion of radiotherapy and chemotherapy to a resection surgery 
modestly improves the survival, GBM is inherently resistant 
to treatments resulting in a median survival of 14.6 months.2
GBM cells dynamically respond to their local microenvi-
ronment, thereby affecting tumor cell behavior.3,4 Important 
components of the tumor microenvironment include: (a) 
non-neoplastic cells near or within the tumor, (b) extracel-
lular matrix, which is a scaffold surrounding the tumor cells 
enriched in hyaluronic acid, and (c) soluble signals such as 
growth and differentiation factors.5,6 Non-neoplastic cells as-
sociated with GBM are glial, immune, microglial, vascular 
endothelial, pericytic and neuronal in nature. Glial cells—
predominantly astrocytes—are the most abundant cells in the 
brain.7
Microglia (MG) cells are important for maintaining brain 
homeostasis. In the resting state, they act as a sentinel, and 
with activation show plasticity along with two broadly de-
fined phenotypes as: (a) pro-inflammatory, classical, and 
anti-tumoral or (b) anti-inflammatory, alternative, or pro-tu-
moral. These two subpopulations differ with respect to cy-
tokine and chemokine production, receptor expression, and 
effector function.8-11 MG, which can comprise up to 35%-
50% of the tumor,8 have been shown in a few reports to stim-
ulate proliferation and invasion of GBM cells in vitro and in 
vivo.12-15 However, little is known whether MG cells mediate 
effects on the response of GBM to cytotoxics.
In addition to these non-neoplastic cells, a 3D extracellu-
lar matrix has been reported to influence tumor cell behavior 
and response to cytotoxics, when compared to the standard 
2D monoculture.16-18 Comprising ~20% of the tissue volume, 
brain extracellular matrix contains few fibrous proteins and 
high amounts of proteoglycans, glycosaminoglycans (GAGs), 
and glycoproteins.3,4 Hyaluronic acid—a negatively charged, 
unbranched GAG—is highly abundant in the brain matrix. In 
the healthy brain, high molecular weight (106 Da) hyaluronic 
acid chains act as the organizational center of the matrix, in-
teracting with proteins to create a hydrogel-like mesh.19
In GBM, hyaluronic acid matrix is upregulated and con-
tributes to many phenotypic alterations associated with tumor 
progression, including cell proliferation, invasion, and drug 
resistance.20,21 The soluble signals and differentiation fac-
tors in the serum-supplemented media also influence cell 
growth and interaction with exogenous factors.22 In fact, it 
has been revealed that human serum stimulates the growth of 
human mammary tumor cells in culture,22 thus implying the 
significance of human serum in modeling a tumor microen-
vironment. In our laboratories, human serum supplementa-
tion has also been shown to modulate both protein and gene 
expression in human biopsy-derived GBM cells as well as to 
influence cell shape and proliferation.23
Although various microenvironmental features strongly 
influence GBM, current models for therapeutic testing fail 
to account for the complex microenvironment surrounding 
the tumor, and hence may not adequately reflect clinical out-
comes. Multiple studies are focused on GBM-extracellular 
matrix or GBM-non-neoplastic cell (such as astrocytes) in-
teractions using 2D in vitro platforms, however few models 
have been established to study the role of the non-neoplastic 
cells, particularly MG, on GBM in a 3D extracellular matrix 
context. Since within our laboratories we have considerable 
experience of 3D human cell in vitro modeling in the context 
of GBM invasion,24 blood-brain barrier mediated drug deliv-
ery,25 and cancer metastasis,26,27 we decided to begin a mul-
tistage program of developing such 3D models for preclinical 
drug testing of GBM using all human, multicellular, in vitro 
conditions. In the initial study, which we report here, we ex-
plored the influence of MG on proliferation, migration, and 
response to temozolomide (TMZ), clomipramine (CLM), and 
vincristine (VCR) on three human GBM cell lines in human 
serum-supplemented conditions. The three agents used in our 
studies have been previously used widely in various 2D in 
vitro studies using both rat or mouse and human cells in the 
context of GBM therapies. Moreover, human mouse models 
have been used to assess tricyclic agents,28-30 TMZ31 and 
VCR.32 Co-cultures of human MG and GBM were carried 
out in 2D to comprehend the effect of MG in GBM, and 
then to mimic the characteristic environment of GBM, this 
co-culture of GBM and MG was explored in a 3D hyaluronic 
acid-based hydrogel. Therefore, a 2D co-culture allowed us 
to elucidate how the presence of MG cells modulates the re-
sponse to clinically relevant drugs in a panel of GBM tumor 
cells, while a 3D co-culture mimics the tumor microenviron-
ment appearing as a powerful platform for drug screening.
2 |  METHODS
2.1 | Ethics statement
A biopsy from a glioma patient was resected at King's College 
Hospital, London, under Ethics permission LREC00-173/11/
SC/0048 in accordance with a National Research Ethics 
Service and the study was approved through ethic committees 
for the University of Portsmouth and King's College Hospital. 
Patient signed an informed written consent prior to surgery.
2.2 | Cell culture
Three human GBM cell lines were used in this study (U-87 
MG, SNB-19 and UP-007) (Table 1). U-87 MG cells were 
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obtained from the European Collection of Cell Culture, SNB-
19 were obtained from DSMZ German Brain Tumour Bank, 
and UP-007 cells were established in house from a GBM bi-
opsy resected at King's College Hospital. A human MG cell 
line, CHME3, an SV40 large T antigen immortalized human 
foetal microglia cell line,33 was kindly provided by Prof Brian 
Bigger from University of Manchester. Both GBM and MG 
cells were cultured in Dulbecco's modified Eagle medium 
(DMEM, Gibco, Fisher Scientific, Loughborough, UK) sup-
plemented with 10% (v/v) of human serum (Sigma-Aldrich, 
Dorset, UK). All cells were maintained at 37°C in a humidified 
incubator with 5% CO2. Media was changed every 2-3 days, 
and subculturing was carried out by washing cells with Hank's 
balanced salt solution (HBSS, Gibco, Fisher Scientific, 
Loughborough, UK) and incubation with TrypLE express en-
zyme (Gibco, Fisher Scientific, Loughborough, UK).
All cell lines were routinely and regularly screened for 
the presence of mycoplasma using the commercially avail-
able MycoAlert assay kit (Lonza, Basel, Switzerland), as 
described by the manufacturers' instructions. For DNA iso-
lation and cell line authenticity, genomic DNA was isolated 
from cell pellets (5 × 106 cells) using QiaAMP DNA Mini kit, 
(Qiagen, Manchester, UK) as described by the manufactur-
ers' instructions. DNA authentication was carried out using 
Geneprint 10 system (Promega, Southampton, UK) accord-
ing to manufacturers' instructions. DNA (15  ng) was sub-
ject to polymerase chain reaction (PCR) amplification in the 
presence of short tandem repeat (STR) loci, consisting of the 
following primer pairs: TH01, D21S11, D5S818, D13S317, 
D7S820, D16S539, CSF1PO, vWA, TPOX, and Amelogenin, 
for gender identification. Amplification was carried out as 
follows: 96°C for 1 minute, followed by 30 cycles of 94°C 
for 10 seconds, 59°C for 1 minute, and 72°C for 30 seconds, 
followed by 60°C for 10 minutes, 4°C soak. Fragment length 
analysis was done using fluorescence detection following mi-
crocapillary electrophoresis (Eurofins Genomics, Ebersberg, 
Germany), and DNA profile was compared with known da-
tabase standards. We also DNA fingerprinted cells using an 
in house-developed microfluidic electrophoresis system in-
corporating a 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA) to analyze short tandem repeat PCR frag-
ments from 10 human genomic loci of human cell lines.34
2.3 | Cell labeling
Cell labeling optimization screening was performed with 
all GBM cells and MG using the CellTrace carboxyfluo-
rescein succinimidyl ester (CFSE) and a CellTrace Far Red 
(Invitrogen, Fisher Scientific, Loughborough, UK), respec-
tively. For the labeling, cells were incubated with TrypLE 
Express for 3 minutes, centrifuged, and resuspended in 1 mL 
of HBSS (with Ca2+ and Mg2+). GBM cells were incubated 
with CellTrace CFSE (5-10 μM) and CHME3 cells incubated 
with CellTrace Far Red (1 μM) in HBSS for 20 minutes at 
37°C. Afterward, to remove unconjugated CellTrace, cell 
suspensions were incubated with DMEM supplemented with 
5% (v/v) human serum for 5 minutes at room temperature. 
Subsequently, both cells were centrifuged, resuspended in 
complete DMEM, and analyzed in a Counter II FL Automated 
Cell Counter to assess the number of cells and viability.
2.3.1 | Cell labeling efficacy
To evaluate the efficacy of the labeling, CFSE+ GBM cells 
and Far Red+ CHME3 cells were seeded at 20 000 cells/cm2 
in a 24-well plate in DMEM supplemented with 10% (v/v) 
human serum and allowed to grow up to 9 days. On Days 1, 
3, 5, 7, and 9, cells were analyzed by flow cytometry to quan-
tify the remaining percentage of labeled cells. CFSE+ GBM 
cells (U-87 MG, SNB-19, and UP-007) were detected using 
the blue 488 laser and the 530/30 channel (FL1). Far Red+ 
MG cells were excited with the red laser 635 and detected 
with a 661/16 channel (FL4). Non-stained cells were in-
cluded as a control. Cells were analyzed in the FACS Calibur 
flow cytometer (BD Biosciences, Wokingham, UK) collect-
ing at least 10,000 events. The FlowJo software was used for 
analysis of the data.
2.3.2 | Cell viability
The effect of the CellTrace on the metabolic activity of GBM 
cells (CFSE) and MG (Far Red) was evaluated by the CellTiter 
96 Cell Proliferation Assay (MTS, Promega, Southampton, 
Cell line Sex Age Passagea Location Other
U-87MG Male – 28-31 – –
SNB-19 Male 47 53-56 Left parietal-
occipital lobe
–
UP-007 Male 71 46-50 – Wild-type IDH1
aCell passage of U-87MG and SNB-19 refers to the numbers given by the suppliers and, since these cells have 
been grown for several decades p-numbers would, realistically be far higher than the passage reported on the 
table. UP-007, as an in-house biopsy-derived cell line, is only cell population which carries a real authenticated 
passage number and is thus more heterogeneous in nature. 
T A B L E  1  Details of the GBM cell 
lines
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UK). CFSE+ GBM (U-87MG, SNB-19, or UP-007) or Far 
Red+ CHME3 cells were seeded at 20 000 cells/cm2 in a 96-
well plate in DMEM supplemented with 10% (v/v) human 
serum and allowed to grow up to 9 days. On specific time 
points, the MTS solution was added (20 μL) to each well, and 
cells were incubated at 37°C for 2  hours. Absorbance was 
measured at λ 492 nm using a POLARstar Omega microplate 
reader (BMG Labtech, Ortenberg, Germany). Non-stained 
cells were used as a control in each experiment.
2.4 | MG plasticity
MG were seeded at 20  000 cells/cm2 and allowed to ad-
here for 24 hours. Afterward, the medium was replenished, 
and cells were treated for additional 48  hours with either 
1 µg mL−1 of lipopolysaccharides (LPS) (Sigma, Gillingham, 
UK) plus 20  ng  mL−1 of Interferon-ɣ (IFN-ɣ) (PeproTech 
Inc, New Jersey, USA) to drive the MG toward a pro-inflam-
matory phenotype or with 20 ng mL−1 of interleukin-4 (IL-
4) (PeproTech Inc, New Jersey, USA) plus 20 ng mL−1 of 
interleukin-13 (IL-13) (PeproTech Inc, New Jersey, USA) to 
drive the MG toward an anti-inflammatory phenotype. Cells 
in standard culture conditions were used as a control.
2.4.1 | Quantitative real-time polymerase 
chain reaction
Total mRNA was isolated from CHME3 cells with RNeasy 
Mini Kit (Qiagen, Manchester, UK). Quantification and in-
tegrity of the extracted mRNA was performed by spectropho-
tometry with measurement of absorbance at 260 and 280 nm 
in a NanoVue Plus Spectrophotometer (GE Healthcare, 
Freiburg, Germany). The cDNA was synthesized from 1 µg 
of RNA by reverse transcription using the High-Capacity 
cDNA Reverse Transcription Kit (ABI Applied Biosystems, 
Life Technologies Europe, Bleiswijk, Netherlands) in a re-
action volume of 20 µL. All primers designed for reference 
and target genes were based on sequences published on the 
GeneBank, National Centre for Biotechnology Information 
(NCBI). BLAST searches were performed to confirm the 
total gene specificity of the primer sequences. Primer se-
quences are listed in the Supplemental Table 1, and were ob-
tained from Invitrogen (Life Technologies Limited, Paisley, 
UK). The RT-qPCR was performed in duplicate using 
PowerUP SYBR Green Master Mix (Applied Biosystems, 
Thermo Fisher Scientific Baltics UAB, Vilnius, Lithuania), 
a LightCycler 96 system (Roche, Mannheim, Germany), in 
a final volume of 12 µL containing 20 ng of cDNA, accord-
ing to the following protocol: initial incubation at 50°C for 
2 minutes plus 95°C for 2 minutes, followed by 45 cycles of 
15 seconds at 95°C, 15 seconds at 60°C, and 60 seconds at 
72°C, followed by melting curve with an increasing from 55 
to 95°C. Normalization was performed using the reference 
gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and the ΔΔCt method.35
2.4.2 | Western blot
After 48  hours of polarization, the MG cells were lysed 
using ice-cold RIPA lysis and extraction buffer (Life 
Technologies Europe BV, Bleiswijk, Netherlands) with 1% 
(v/v) of Halt Protease Inhibitor Cocktail (Thermo Fisher 
Scientific, Pierce Biotechnology, Rochford, USA) for 
30 minutes on ice, then centrifuged at 13 000 g for 10 min-
utes at 4°C. Total protein concentration was determined 
using Coomassie Plus Reagent (Life Technologies Europe 
BV, Bleiswijk, Netherlands). The total protein (20  µg) 
was denatured using NuPAGE sample reducing agent and 
NuPAG LDS sample buffer (Life Technologies Europe BV, 
Bleiswijk, Netherlands) for 5 minutes at 95ºC, resolved on 
a Mini-PROTEAN TGX 12% (w/v) SDS polyacrylamide 
Precast Gel (Bio-Rad, Hertfordshire, UK), and immunob-
lotted onto a 0.2-μm nitrocellulose membrane (Schleicher 
and Schuell, Dassel, Germany). The membranes were 
blocked for 1  hour with blocking buffer consisting of 5% 
(w/v) bovine serum albumin (BSA, phosphorylated forms) 
or 5% (w/v) fat-free dry milk (total forms) in Tris-buffered 
saline (TBS)-Tween 20 (0.05%  (w/v)) (TBS-T, pH 7.5) 
and then incubated with the primary antibody of choice for 
16 hours at 4°C (1:1000 in 5% (w/v) BSA). All primary an-
tibodies were obtained from Cell Signaling (New England 
Biolabs, Hertfordshire, UK): phospho-STAT1 (Tyr701) 
(58D6), STAT1 (D1K9Y), phospho-NF-κB p65 (Ser536) 
(93H1), NF-κB p65 (E498), phospho-STAT6 (Tyr641), 
STAT6, phospho-STAT3 (Tyr705) (D3A7), STAT3, and 
GAPDH (14C10). Following primary antibody incubation, 
membranes were washed (3 times for 5 minutes) in TSB-T 
and incubated for 1 hour at room temperature with the re-
quired secondary anti-rabbit IgG, HRP-linked antibody 
(Cell Signaling, New England Biolabs, Hertfordshire) di-
luted 1:10 000 in blocking buffer. Membranes were again 
washed (6 times for 5  minutes) in TSB-T and signals de-
tected using either in a SuperSignal WEST DURA or in a 
FEMTO chemiluminescent substrate (Pierce, Chester, UK). 
Signals were captured on ChemiDocTM XRS+ (BIORAD, 
Hertfordshire, UK).
2.4.3 | Cytokine array
Soluble factors secreted by MG were evaluated by Human 
XL Cytokine Array (R&D Systems, Minneapolis, USA). 
Cell culture supernatants were collected after 48  hours of 
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polarization, and the unstimulated cells were used as a con-
trol. The collected cell culture supernatants were centrifuged 
to remove any particles and use for analysis immediately ac-
cording to the kit instructions.
2.5 | 2D co-cultures: Cell viability and 
proliferation
Co-cultures of the GBM (U-87 MG, SNB-19 or UP-007) and 
MG were established by seeding both cell lines in a 24-well 
plate at a final density of 20 000 cells/cm2. CFSE+ GBM and 
Far Red+ CHME3 cells were cultured either alone (40 000 
cells) or cultured in co-culture at the following ratio of GBM 
to CHME3 cells: 90:10 (36 000:4000), 80:20 (32 000:8000), 
or 50:50 (40  000:40  000). Cells were allowed to grow in 
close contact for 3 days.
2.5.1 | Cell imaging
Co-cultures were cultured for 3  days and, subsequently, 
fixed using paraformaldehyde solution, 4% (w/v), for 
15  minutes at room temperature. Cells were washed and 
stored at 4°C. Imaging was carried in a LSM719 confocal 
laser-scanning microscope (Zeiss, Oberkochen, Germany) 
using a Plan Apochromatic 20×/0.8 M27 objective (NA 
0.8). All images were acquired using sequential acquisi-
tion of the different channels to avoid cross-talk between 
CellTrace with a pinhole adjusted to one airy unit. Images 
were processed with Zen 2009 Light Edition (Zeiss, 
Oberkochen, Germany).
2.5.2 | Cell viability
To evaluate viability of the cells in co-culture (GBM and 
CHME3), cells were incubated with TrypLE express en-
zyme for ~3 minutes, centrifuged, and resuspended in HBSS. 
Propidium iodide (Sigma-Aldrich, Dorset, UK) was added 
at the final concentration of 50 μg mL−1 and incubated for 
5 minutes protected from the light. Cells were washed with 
HBSS and analyzed in FACS Calibur flow cytometer, as pre-
viously described. In addition to the aforementioned chan-
nels, propidium iodide-positive cells were detected using the 
blue 488 laser and the 630/30 channel (FL3). FlowJo soft-
ware was used for analysis of the data.
2.5.3 | Cell proliferation
Cell proliferation was quantified by relation to the inverse 
of the fluorescence intensity of CFSE+ GBMs and Far Red+ 
CHME3. Both CellTrace molecules readily diffuse into 
cells and bind covalently to intracellular amines in proteins 
resulting in stable, well-retained fluorescent staining. The 
fluorescence intensity of the CellTrace is diminished with 
an increase of cell division as the reagent is passed through 
generations resulting in an inverse correlation between flu-
orescence intensity and cell proliferation. Thus, cells were 
analyzed by flow cytometry, as previously described, and 
using FlowJo software fluorescence intensity for each chan-
nel (FL1 or FL4) was obtained. Proliferation was calculated 
in relation to a control of cells growing in monoculture ac-
cording to Equation (1):
where A represents the cells growing in a co-culture (90:10, 
80:20, 50:50 ratio of GBM to MG) and B is the control of 
cells growing in the monoculture (GBM or MG). The cell 
proliferation is expressed in function of the cells growing in 
a monoculture.
2.6 | 2D co-cultures: Cell migration
Linear cell migration was evaluated using a scratch-wound 
assay. Cells, either in a mono- or co-culture, were seeded 
at 100 000 cells/cm2 in a 24-well plate and allowed to grow 
to a confluent monolayer over 24 hours. Afterward, a lin-
ear scratch was done using a 200 μL pipette tip. Following 
injury, wound closure was observed using EVOS FL Auto 
2 Cell Imaging System (Fisher Scientific, Loughborough, 
UK) equipped with a cell imaging chamber under a hu-
midified atmosphere (37°C, 5% CO2). Images were ac-
quired every 30 minutes over a period of 24 hours. Image 
analysis was performed using Image J, and rate of closure 
(μm/hour) was calculated by plotting distance of the wound 
gap versus time at different time points (0, 4, 8, 12, and 
18 hours).
Cell migration was evaluated using a Transwell assay 
(8  μm pore size, a polycarbonate membrane, Corning, 
Loughborough, UK). Briefly, GBM cells (U-87 MG, SNB-
19 or UP-007) were seeded in the upper compartment of a 
Transwell at 100 000 cells/cm2 and maintained in a monocul-
ture or in co-culture with CHME3 cells seeded in a 24-well 
plate at 100 000 cells/cm2. After a co-culture for 24 hours, cells 
on the top compartment were removed and the Transwells 
were fixed in 70% (v/v) ethanol for 10 minutes. Transwells 
were allowed to dry for 10 minutes and stained with a 0.2% 
(w/v) Crystal Violet (ACROS Organics, Loughborough, UK) 
solution for 10 minutes at room temperature. The migrating 
GBM cells accumulating on the other side of the Transwell 
membrane were quantified using ImageJ. Threshold was 
(1)Proliferation (% ) =
(
1
(A/B)
)
×100
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attuned and particle analysis was performed to obtain the 
total number of cells.
2.7 | 2D co-cultures: Drug response
GBM (U-87 MG, SNB-19 or UP-007) or CHME3 cells 
were seeded at 20  000 cells/cm2 in a 96-welll plate and 
allowed to grow for 24  hours. Subsequently, the cells 
were treated with the cytotoxics: temozolomide (TMZ, 
Sigma-Aldrich, Dorset, UK), clomipramine (CLM, Sigma-
Aldrich, Dorset, UK), or vincristine (VCR, Tocris, Bristol, 
UK) to calculate an IC50 value for each cell line. TMZ was 
dissolved in dimethyl sulfoxide at 1 mM, and working so-
lutions were prepared from 200 to 1000  μM in DMEM. 
CLM was dissolved at 50 mM in water, and solutions were 
prepared at concentrations ranging 20-100 μM in DMEM. 
VCR sulfate was dissolved in water at 1 mM and working 
solutions were used from 2 to 10 μM in DMEM. After drug 
treatment, cells were incubated for 2  days, and viability 
was measured by CellTiter 96 Cell Proliferation Assay, as 
previously described. IC50 values were calculated using 
GraphPad Prism 7.03 software (GraphPad, California, 
USA).
To evaluate the influence of MG in GBM drug response, 
co-cultures in 2D were established as previously described, 
and cells were treated with TMZ (400 μM), CLM (20 μM) 
or VCR (2 μM). Following 48 hours of drug treatment, cells 
were analyzed by flow cytometry using a FACS Calibur 
collecting 10 000 events. The FlowJo software was used for 
analysis of the data, and cell proliferation was calculated 
using Equation (1). Untreated cells were used as a negative 
control and unlabeled cells were used as a control for the flow 
cytometry analysis.
2.8 | 3D co-cultures: Cell viability and 
proliferation
Cells were grown, either in mono- or co-culture, in a 3D 
HyStem-HP hyaluronic acid-based hydrogel (Sigma-Aldrich, 
Dorset, UK). HyStem-HP hydrogel is formed when the 
crosslinking agent Extralink (polyethylene glycol diacrylate 
Mw 3400 g/mol) is added to a mixture of HyStem-HP (thiol-
modified hyaluronan) and Gelin-S (thiol-modified gelatin). 
Hydrogel was prepared according to the manufacturers' in-
structions. Both GBM (UP-007) and MG cells were grown in 
monoculture or in a co-culture at the ratio of 50:50 in the hya-
luronic acid-based hydrogel. Briefly, UP-007 and CHME3 
cells were labeled with CellTrace CFSE and Far Red, respec-
tively, and encapsulated within the liquid hydrogel precursor 
solution at 1 × 106 cells mL−1.36 Hydrogels were allowed to 
polymerise for 20 minutes, and then complete DMEM media 
was added to each well. Cells in 3D were allowed to grow 
for 3 days.
2.8.1 | Cell viability
To evaluate the cell viability within the hydrogel, HyStem-HP 
was prepared and cells were mixed with the liquid precur-
sor solution (50 μL hydrogel per well in 96-welll plate, 
50 μL of DMEM). Cells were allowed to grow for 3 days, 
and CellTiter 96 Assay was carried out as described previ-
ously. Cell viability was additionally quantified by staining 
with propidium iodide (Sigma-Aldrich, Dorset, UK). The 
HyStem-HP hydrogel containing cells (UP-007, CHME-3 or 
UP-007:CHME3 at 50:50) was dispensed in μ-slide 18-well 
flat (IBIDI, Glasgow, UK) (15-μL hydrogel per well, 15 μL 
of DMEM), and cells allowed to grow for 3 days. Cells were 
incubated with propidium iodide solution (50 μg mL−1) for 
10 minutes at 37°C for detection of dead cells. After incu-
bation, the cells were washed with phosphate-buffered sa-
line (PBS) and observed under the LSM710 confocal laser 
microscope.
2.8.2 | Cell proliferation
The HyStem-HP hydrogel containing cells (UP-007, 
CHME-3 or UP-007:CHME3 at 50:50) was dispensed in 
μ-slide 18-well flat slide (IBIDI, Glasgow, UK) (15-μL hy-
drogel per well in 15 μL of DMEM), and cells allowed to 
grow for 3 days. Afterward, the cells were imaged under a 
LSM710 confocal laser microscope. Images were obtained 
from three replicates. Cell fluorescence intensity was quanti-
fied using ImageJ by obtaining integrated density of CFSE+ 
cells.37
2.9 | 3D co-cultures: Drug response
To evaluate the influence of MG in GBM drug response 
when in 3D, co-cultures were established either in a 96-well 
plate (50 μL hydrogel per well, 50 μL of DMEM) or in 18 
well-flat slide (15-μL hydrogel per well in 15 μL of DMEM) 
containing 1 × 106 cells mL−1 of gel. GBM cells were ei-
ther cultured in monoculture or co-culture at a ratio of 50:50 
with MG. Hydrogels were prepared and dispensed in the 
wells, and cells were allowed to grow for 24  hours within 
the hydrogel. Afterward, TMZ (400 μM), CLM (20 μM) or 
VCR (2 μM) was added to each well and cells incubated for 
48  hours. Untreated cells were used as a control for each 
model (2D or 3D in a mono- or co-culture). Following the 
48  hours, CellTiter 96 assay was performed as previously 
described to determine the cell viability in each model. To 
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assess cell proliferation, cells cultured in an 18-well flat slide 
were observed under LSM710 confocal laser microscope, 
and fluorescence of CFSE+ GBM cells was analyzed as 
aforementioned using ImageJ.
2.10 | Statistical analysis
The results are expressed as mean  ±  standard error of the 
mean (SEM). Comparisons between groups were obtained 
by One-Way ANOVA using Dunnett's post hoc test in the 
comparison to a control or Tukey's for multiple comparisons 
between groups in GraphPad Prism 7.03. A significance level 
of P <  .05 was considered statistically significant. In each 
experiment, N = 3 replicates for each condition and displayed 
data represent the mean of three independent experiments.
3 |  RESULTS
3.1 | Optimization of the labeling of GBM 
and MG cells
In order to establish co-cultures to further elucidate the influ-
ence of MG on the behavior of GBM, the labeling of each 
cell type was optimized using CellTrace dyes. Three GBM 
cell lines (U-87 MG, SNB-19, UP-007) were stained using 
CFSE CellTrace and, as depicted on the Figure 1A,B, the 
F I G U R E  1  Labeling and viability of GBM and MG cells marked with CellTrace. A, Percentage of CFSE+ U-87 MG, SNB-19, and UP-007 
cells along 9 days of culture. Percentage of CFSE-labeled cells is given compared to an unstained control. B, Viability of U-87 MG, SNB-19, and 
UP-007 cells stained with CellTrace CFSE (5 μM) compared to a control of unstained cells. C, Percentage of Far Red+ CHME3 cells along 9 days 
of culture. D, Viability of CHME3 stained with CellTrace (1 μM) when compared to a control of unstained cells. E, Histogram of the frequency of 
distributions of the labeling of CFSE+ GBM cells showing a decrease of fluorescence intensity along the days of culture even though the whole cell 
population remains positive for CFSE. Mean ± SEM (N = 3, mean of three independent experiments). P > .05 when comparing cell viability of 
GBM or CHME-3 labeled cells (CFSE and Far Red, respectively) to unlabeled cells
8 |   LEITE ET aL.
percentage of CFSE+ cells remained >95% for 7  days of 
culture showing no significant effects on cell viability. With 
GBM labeled with CFSE CellTrace, the human microglia 
cell line (CHME3) was labeled with a Far Red CellTrace to 
obtain a reliable labeling that allows a clear distinction be-
tween the two cell populations (GBM and MG). Using Far 
Red CellTrace (1 μM), MG cells remain Far Red+ for 9 days 
in culture (Figure 1C) and viable when compared to unstained 
cells (Figure 1D). Fluorescence intensity of CellTrace dyes 
showed a decrease along the days of culture, as represented in 
Figure 1E, indicating that the cells remain proliferating pass-
ing the dye to the daughter cells. Figure 2 illustrates dot plots 
of a mixture of CFSE+ GBM and Far Red+ MG showing a 
complete and effective resolution of the two populations, 
which allows for a specific analysis of each of the popula-
tions in terms of viability, proliferation, and drug response.
3.2 | CHME3 cells display ability to 
be activated
To investigate the ability of CHME3 cells to respond an exter-
nal stimulus, CHME3 cells were stimulated either with LPS 
and IFN-γ to drive a pro-inflammatory phenotype, or with IL-4 
and IL-13 to drive an anti-inflammatory phenotype (Figure 3). 
Cell activation at the transcriptional level was studied by RT-
qPCR, as shown in Figure 3A. When stimulated with LPS 
and IFN-ɣ for 48 hours, CHME3 cells showed an increased 
trend (relative to unstimulated cells—dashed line) for a raised 
expression for all cytokine genes examined. As expected, 
significant increases in expression were found for the pro-
inflammatory cytokines: interleukin-1β (IL-1β, ~2.2-fold), 
interleukin-6 (IL-6, ~5.7-fold), interleukin-12 (IL-12, ~1.5-
fold), C-X-C motif chemokine 10 (CXCL10, ~473-fold), and 
tumor necrosis factor alpha (TNF-α, ~2.1-fold) (Figure 3A). 
These results were further corroborated by cytokine array, 
which show an increased trend for the protein levels in stimu-
lated CHME3 cells (Figure 3B). Pro-inflammatory cytokines 
CXCL10, IL-6, and TNF-α increased ~61.4-, 2.8-, and 1.6-
fold, respectively, when stimulated with LPS and IFN-γ, as 
depicted in Figure 3B. Any alteration to IL-1β, IL-12, and 
IL-10 was observed with stimulation with LPS and IFN-γ. 
Compared to the unstimulated cells, activation of some anti-
inflammatory cytokines was also evident, notably, C-C motif 
chemokine 22 (CCL22, ~2.0-fold), and the scavenger recep-
tor, CD163 (~3.1-fold) (Figure 3A). When CHME3 cells were 
challenged with IL-4 and IL-13, there was also a trend for a 
raised expression for all cytokine genes examined, although 
that was less pronounced compared to the one seen with LPS 
and IFN-ɣ (Figure 3A). In terms of cytokine levels, when MG 
cells were stimulated with IL-4 and IL-13, a slight decrease 
of IL-1β, IL-6, IL-12, and IL-10 was observed; however, no 
alterations were found on CXCL10 and TNF-α (Figure 3B). 
The western blot data (Figure 3C,D) confirmed that CHME3 
cells can display differential responsiveness following expo-
sure to classical microglial activators. Here, the transcription 
factors characterizing microglial pro-inflammatory (STAT1, 
NF-kB p65) or anti-inflammatory (STAT6, STAT3) pheno-
types were studied including their respective phosphorylation 
state. CHME3 cells, when exposed to LPS and INF-ɣ, showed 
an appropriate activation of pSTAT1 (~5.7-fold increase) and 
pNF-kB p65 (~2.5-fold increase). An exposure to IL-4 and 
IL-13 triggered appropriate activation of STAT6 (~49-fold 
increase) in CHME3 cells as observed by western blot. No 
alterations were observed in the levels of STAT3.
3.3 | MG support GBM growth and  
migration
To directly assess the effect of MG on GBM behavior, we 
established co-cultures of CFSE+ GBM cells and Far Red+ 
F I G U R E  2  Two-dimensional dot plots showing mixed populations of CFSE+ GBM and Far Red+ MG. Dot plots illustrating mixtures of 
live Far Red+ CHME3 cells with CFSE+ U-87 MG (A), SNB-19 (B), and UP-007 (C) after 3 days of culture. The X-axis shows the intensity in the 
CFSE (FL1) channel and the Y-axis fluorescence intensity in the Far Red channel (FL4). The quadrants are defined by the intensity value of the 
unstained cells, which are within the lower left quadrant of the plots. Right bottom quadrant (CFSE+/Far Red−) comprises GBM cells, while left top 
quadrant (CFSE−/Far Red+) represents MG cells
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MG at ratios of 90:10, 80:20, and 50:50. The rationale for the 
use of different GBM to MG ratios is based on the evidence 
that MG cells can be as high as 50% in a malignant brain 
tumor,8 and that this percentage of MG rises with the grade 
of malignancy.38 As a control, GBM and MG were grown in 
a monoculture. In all the tested co-culture ratios of GBM to 
MG cells, both cells presented the ability to grow together 
establishing close contact and, as displayed on Figure 4A, 
GBM and MG remained viable (viability >95%) in co-culture 
(Figure 4B). Furthermore, to study the effects of co-culture 
in both MG on GBM growth, fluorescence intensity of each 
CellTrace (CFSE or Far Red) was used as an indirect meas-
ure of cell proliferation following flow cytometry analysis 
(Figure 4C). In all three tested GBM cell lines, the presence 
of MG in culture resulted in an increase in cell proliferation 
of GBM (U-87 MG: ~17%; SNB-19: ~30%; UP-007: ~19% 
increase compared to monoculture of GBM, P  <  .001) at 
a higher percentage of MG cells (50% MG). Interestingly, 
SNB-19 cells demonstrated high proliferation (P < .05) even 
when cultured with a low percentage of MG (10%-20% MG). 
Additionally, the effect of MG on GBM migration was as-
sessed using scratch-wound and Transwell assays (Figure 5). 
Initially, we performed a scratch-wound assay on the three 
different GBM confluent cells either alone or in a contact 
co-culture with MG (Figure 4A, Supplemental Figure 1). As 
depicted on Figure 5A, U-87 MG and UP-007 when in a co-
culture with MG showed no significant difference (P > .05) 
in terms of rate of closure of the gap compared to a mono-
culture of GBM. However, when comparing the co-cultures 
to a monoculture of MG, MG cells presented a statistically 
significant lower rate of closure. The lower rate of closure 
of MG might result in no differences between GBM in 
mono- and co-culture, which gives no clear results regarding 
migration of GBM cells. Nonetheless, the SNB-19 cells dem-
onstrated a similar rate of closure to MG monoculture, which 
allows us to observe a significant effect on cell migration of 
SNB-19 when in co-culture with MG at a high percentage 
of MG (50%). In the presence of MG, SNB-19 migration in 
the wound-scratch assay showed a 1.73-fold increase in com-
parison to monocultures the SNB-19 (Figure 5A). To further 
F I G U R E  3  Polarization of CHME3 MG. A and B, mRNA expression (A) and soluble factors (B) from CHME3 cells either stimulated either 
with LPS and IFN-γ or IL-4 and IL-13. C and D, Phosphorylation of STAT1, NF-kB, STAT6, and STAT3 by CHME3 cells (C) and respective 
quantification (D). CHME3 cells were stimulated for 48 h either with LPS and IFN-ɣ toward pro-inflammatory or with IL-4 and IL-13 to induce an 
anti-inflammatory phenotype. Unstimulated cells were used as a control. Results normalized to unstimulated CHME3 cells. Mean ± SEM (N = 3, 
mean of three independent experiments). *P < .05, **P < .01, ***P < .001, ****P < .0001 compared to untreated CHME3 cells. The dashed lines 
in 3A, 3B, and 3D shows the respective level of normalized expression, that is, 1, in unstimulated CHME3 cells
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clarify the role of MG on GBM migration, a Transwell assay 
was carried out (Figure 5B,C). We established the co-culture 
in the Transwell, in which GBM are seeded on top of the 
membrane and allowed to migrate toward the MG cells on 
the bottom compartment. Based on the results obtained in 
terms of GBM cell proliferation and migration at the differ-
ent ratios of MG, co-cultures were tested at a ratio of 50:50 
of GBM to MG for the three GBM cell lines. Migration of 
all GBM cells was significantly increased: U-87 MG, 1.45-
fold (P > .01), SNB-19, 3.71-fold (P > .001), while UP-007, 
a 2.48-fold increase (P  >  .001), comparing to a culture of 
GBM without MG.
3.4 | MG modulates sensitivity to cytotoxics 
in GBM
Following the study on the influence of MG cells on the pro-
liferation and migration of GBM, we tested the role of MG 
on the sensitivity to three cytotoxics (TMZ, CLM, and VCR) 
in the GBM cells (Figure 6). To obtain an effective dose 
for each drug, dose-response was carried out at a range of 
concentrations, and the IC50 values were obtained (Table 2, 
Supplemental Figure 2). In all GBM cell lines, treatment with 
TMZ (200-1000 μM) resulted in a reduction of cell viability 
up to ~75%-80% (Supplemental Figure 2), and with the range 
F I G U R E  4  Viability and proliferation of GBM and MG cells growing in contact co-culture in 2D for 3 days. A, Representative images of 
CFSE+ UP-007 and Far Red+ CHME3 cells in co-culture at ratios of 90:10, 80:20, and 50:50 after 3 days of culture. Scale bar: 50 μm. B, Cell 
viability of U-87 MG, SNB-19, and UP-007 cells expressed as the percentage of propidium iodide (PI) negative cells quantified by flow cytometry. 
GBM cells culture in a contact co-culture with MG at a GBM:MG ratio of 90:10, 80:20, and 50:50. C, Proliferation of GBM and MG cells in 
contact co-culture at GBM:MG ratio of 90:10, 80:20, and 50:50 determined by flow cytometry. U-87 MG, SNB-19, and UP-007 proliferation 
expressed in relation to the control cells growing in a monoculture in 2D. Mean ± SEM (N = 3, mean of the three independent experiments). 
*P < .05, **P < .01, ***P < .001 compared to the monoculture either GBM or MG
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of concentrations tested an IC50 value was not obtained. 
However, in CLM and VCR, the IC50 values for each cell 
line were calculated with CLM and VCR having IC50 values 
<30 μM (Table 2). Based on these results, a concentration 
within the IC50 range of CLM (20 μM) and VCR (2 μM) was 
used in GBM and MG co-cultures. For TMZ, the concentra-
tion of 400 μM was chosen for further studies. When treated 
with TMZ, the MG cells seemed not to statistically impact 
on sensitivity of GBM cells; however, a slight increase in 
proliferation of the GBM in co-culture with MG is observed 
(Figure 6A). On the other side, CLM- and VCR-treated GBM 
cells in co-culture with MG displayed a higher resistance to 
these cytotoxics even in the presence of a low amount of MG 
(10%-20%) (Figure 6B,C, P < .05).
F I G U R E  5  Migration of GBM in 2D co-cultures with MG cells. A, Rate of closure of the wound in a scratch assay with U-87 MG, SNB-
19, and UP-007 co-cultures with MG at a GBM to MG ratio of 90:10, 80:20, and 50:50. The wound closure was followed for 18 h. B, Number of 
GBM migrating cells in a Transwell assay with U-87 MG, SNB-19, and UP-007 in co-culture with CHME3 at the ratio of 50:50. C, Representative 
micrographs of the migrating cells in Transwell assay containing U-87 MG, SNB-19, or UP-007 in co-culture with MG. Scale bar: 200 μm. 
Mean ± SEM (N = 3, mean of the three independent experiments). ••P < .01 compared to the monoculture of SNB-19. *P < .05, **P < .01, 
***P < .001 compared to monoculture of MG
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3.5 | 3D co-culture model reflects 
influence of MG on GBM
The results obtained with the 2D co-cultures of GBM and 
MG demonstrated the effect of MG on the behavior of 
three GBM cell lines in human serum-supplemented media. 
Although these results demonstrate the relevance of non-ne-
oplastic cells in in vitro models of GBM, the 3D environment 
is a key parameter to be considered. Thus, we established a 
3D co-culture of GBM and MG by using a hyaluronic acid-
based hydrogel aiming to mimic extracellular matrix (ECM) 
F I G U R E  6  Response of GBM to TMZ, CLM, and VCR when in co-culture with ratios of MG in 2D. A, Proliferation of U-87 MG, SNB-19, 
and UP-00 in mono- or co-culture with MG when treated with TMZ at 400 μM for 2 days. B, U-87 MG, SNB-19, and UP-007 cell proliferation in 
a mono- or co-culture with MG after treated with CLM (20 μM) for 2 days. C, Proliferation of U-87 MG, SNB-19, and UP-007 cells in co-culture 
with MG when treated with VCR at 2 μM for 2 days. Co-cultures of GBM and MG were established at the ratios of 90:10, 80:20, and 50:50 of 
GBM to MG. Proliferation is expressed in relation to a control of GBM cells growing in monoculture. Mean ± SEM (N = 3, mean of the three 
independent experiments). *P < .05, **P < .01, ***P < .001 in comparison to monoculture of GBM
T A B L E  2  IC50 values of TMZ, CLM, and VCR in three GBM 
cell lines and MG
  TMZ (μM) CLM (μM) VCR (μM)
GBM
U-87 MG >1000 16.37 ± 1.53 3.60 ± 0.62
SNB-19 >1000 27.83 ± 1.82 26.84 ± 17.45
UP-007 >1000 6.92 ± 1.77 6.48 ± 2.20
MG
CHME3 >1000 4.42 ± 2.73 2.62 ± 0.56
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of the tumor (Figure 7). As UP-007 cell line is a more re-
alistic representation of a GBM, this biopsy-derived cell 
line was selected for the 3D studies using a ratio of GBM to 
MG of 50:50. In terms of cell viability, a Cell Triter 96 Cell 
Proliferation assay displays that cells, either in the mono- or 
co-culture, growing in 3D remained viable when comparing 
to the 2D cultures (Figure 7A). In addition, cells growing in 
the 3D system were stained for propidium iodide for calcula-
tion of dead cells (Figure 7B). The viability of GBM cells 
in the 3D hydrogel was not altered by the presence of MG 
(Figure 7B). However, in terms of cell proliferation, GBM 
cells growing in a co-culture with MG in 3D demonstrated 
greater proliferation (Figure 7C). Thus, these results reflect 
the data obtained in the 2D co-cultures, confirming that MG 
and GBM grown in close contact (Figure 7D) and that pro-
motes proliferation of GBM. In 2D cultures, a ~19% increase 
in proliferation in GBM UP-007 cells was observed, while 
in the 3D culture in hyaluronic acid, a ~69% increase is ob-
tained in a GBM to MG ratio of 50:50, suggesting that the 
3D hyaluronic acid-based ECM further supports the role of 
MG in GBM.
The 3D co-culture model developed was challenged with 
TMZ, CLM, and VCR in order to establish a comparison 
to the 2D co-culture model (Figure 8). Cell viability was 
assessed by Cell Triter 96 Cell Proliferation assay of the 
mono- and co-cultures of GBM and MG at a ratio of 50:50 
in 2D and 3D when treated with a dose of TMZ, CLM, or 
VCR. In the 3D environment, a dose of CLM and VCR 
F I G U R E  7  Cell viability and proliferation of GBM and MG cells in a 3D co-culture. A, Viability of mono- and co-cultures of GBM 
and MG in the hyaluronic acid hydrogel, HyStem-HP, compared to the 2D cultures. Viability was obtained by Cell Triter 96 Cell Proliferation 
assay after 3 days of culture. B, Viability of GBM cells in mono- or co-culture with MG in 3D system obtained by the number of propidium 
iodide (PI) negative GBM cells. C, Proliferation of GBM and MG cells in mono- or co-culture represented by the CFSE+ GBM and Far Red+ 
MG fluorescence. Fluorescence intensity is inversely related to proliferation. D, Representative image of a co-culture of UP-007 and CHME 
in 3D hydrogel. Scale bar: 100 μm. Mean ± SEM (N = 3). *P < .05 in comparison to monoculture of GBM
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triggered the decrease of cell viability of GBM; however, 
a co-culture with MG caused the survival of >100% of the 
population in response to the CLM and VCR (Figure 8A). 
GBM and MG co-cultured in the hydrogel exhibit a 2.5- and 
1.7-fold increase in cell viability comparing to the mono-
culture of GBM in 3D when treated with CLM and VCR, 
respectively (P < .001). The addition of TMZ resulted in no 
statistically significant difference in the mono- and co-cul-
tures (Figure 8A, P  >  .05); however, a slight increase in 
viability is observed when comparing both conditions in 2D 
and 3D. Although these results in terms of cell viability 
appear to illustrate the drug resistance of GBM when in 
contact with MG, the Cell Triter 96 Cell Proliferation assay 
gives an overall viability of the whole co-culture system 
and not a specific effect on the GBM. In order to further 
elucidate the response of GBM, cell fluorescence intensity 
of CFSE+ UP-007 cells treated with TMZ, CLM, and VCR 
was quantified as a measure of cell proliferation (Figure 
8B). In terms of cell proliferation, the dose of TMZ, CLM, 
or VCR did not have a statistically significant effect on 
the monoculture of UP-007 in 3D (P > .05). Nevertheless, 
when comparing the treated mono- and co-cultures in 3D, a 
significant reduction of cell fluorescence was noted for all 
drugs, thus confirming a role for MG in GBM resistance.
4 |  DISCUSSION
Currently, little is known about the role of non-neoplastic 
cells, such as MG cells, and ECM in GBM behavior and 
response to cytotoxics. To understand the impact of MG 
cells in GBM, we established a co-culture model compris-
ing both human GBM (U-87 MG, SNB-19, or UP-007) 
and MG (CHME3) cells cultured under human serum 
supplementation. CHME3 is a human MG cell line able 
to respond to environmental stimuli. Here, we showed the 
CHME3 cells to be responsive to classical pro-inflamma-
tory signal through the Toll-like 4 receptor (TLR4) stimu-
lation by LPS and IFN-γ, leading to activation of STAT1 
and the nuclear factor-kB (NF-kB). This pathway is typi-
cally associated with microglial release of IL-1β, IL-12, 
TNF-α, and IL-6, and with high receptor expression for 
CD80, CD86, and CXCL10. In contrast, IL-4 receptor and 
IL-10 receptor stimulation leads to activation of STAT6 
and STAT3 signaling, respectively, and is typically associ-
ated with microglial release of IL-10, TGF-β, IL-4, the C-C 
motif chemokine ligand 22 (CCL22) and transglutaminase 
2 (TGM2), followed by expression of several receptors, in-
cluding class A scavenger (SR-A, CD204) and mannose 
receptor (CD206), CD163, and CD200R.38
F I G U R E  8  Drug response of GBM cells to TMZ, CLM, and VCR in 2D and 3D culture in mono- or co-culture with MG. A, Viability of 
UP-007 cells when treated with TMZ, CLM, or VCR obtained by Cell Triter 96 Cell Proliferation assay. Cells were either cultured in 2D or 3D 
conditions (HyStem-HP), alone or in co-culture with MG, at a 50:50 ratio for 1 day and treated with cytotoxics for 2 days. Cell viability was 
normalized with untreated cells for each of the model used (2D/3D and mono/co-culture). Mean ± SD (N = 3). *P < .05, ***P < .05 in comparison 
to control (untreated cells). ••P < .01, •••P < .001, as indicated in the figure. B, Corrected total cell fluorescence of GBM cultured in 3D treated 
with TMZ, CLM, or VCR either in mono- or co-culture with MG. Fluorescence intensity is inversely related to proliferation. Mean ± SEM (N = 6). 
*P < .05, **P < .01 comparison to monoculture treated with the TMZ, CLM, or VCR
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Initially, the co-cultures of GBM and MG were explored 
in 2D using a range of ratios of GBM to MG (90:10, 80:20, 
50:50), and then the model was translated to 3D using a 
hyaluronic acid hydrogel to mimic the GBM microenvi-
ronment and comprehend the role of ECM in combination 
with non-neoplastic MG cells. Using three GBM cell lines, 
including an in house established biopsy, we aimed to eval-
uate the influence of tumor heterogeneity in the response 
to MG. With co-cultures under human serum supplemen-
tation, the initial study focused on the identification of the 
different cell types when co-culturing GBM and MG. To do 
so, GBM and MG cells were stained using two amine-re-
active dyes, CellTrace CFSE and Far Red. These amine-re-
active dyes have been described to be superior in peak 
resolution and for a non-specific dye transfer compared to 
the membrane-staining dyes.39,40 CellTrace CFSE and Far 
Red dyes permeate live cells and fluorescently label pro-
teins through covalent interactions with amine groups.41 
Additionally, CellTrace dyes allow tracking the cell pro-
liferation, as at each cell division, fluorescence intensity 
is halved in the daughter cells.40 Thus, CellTrace CFSE 
and Far Red are not only useful to label cells but also to 
track and measure cell proliferation. Our results confirmed 
that CFSE (5 μM) is able to label the GBM cells (~99% of 
CFSE+ GBM up to 7 days in culture) without causing an 
effect in cell viability. Similarly, CellTrace Far Red (1 μM) 
was sufficient to stain MG cells maintaining them viable 
when compared to unstained controls. Analysis by flow cy-
tometry demonstrated that both cell types are specifically 
labeled, and identification of each cell type is possible in a 
mixture of GBM and MG.
In the past couple of decades, glioma infiltrating MG have 
been described to secrete factors, as cytokines, growth factors 
and proteases, which directly or indirectly influence a glioma 
growth.8,42 In GBM, MG cells have been shown to promote 
cell proliferation, and also migration in in vitro non-contact 
co-cultures or by using MG conditioned media.12,13,15,43 The 
exact mechanism is still unclear, however microglial stress 
inducible protein 1 was to shown to be implicated in GBM 
progression in the presence of MG.13 Although MG cells pro-
mote tumor progression, their influence in the human GBM 
drug-response has not yet been described. We therefore in-
vestigated the influence of MG cells in GBM proliferation 
and migration in 2D contact co-cultures with three different 
GBM cell lines. Additionally, to comprehend the significance 
of MG cells in drug-response of GBM cells, co-cultures were 
challenged with cytotoxics (TMZ, CLM, and VCR). TMZ is 
the standard treatment of GBM acting by addition of methyl 
groups to purine bases of DNA,2 and VCR is a vinca alkaloid 
that interacts with β-tubulin inhibiting mitosis.44 CLM is tri-
cyclic antidepressant that has been shown to have selective 
cytotoxicity against glioma cells in vitro by acting via mi-
tochondria and mediating apoptosis45-47 and autophagy.28,29 
CLM was included since not only has been reported to act on 
the GBM cells through a completely different, mitochondrial, 
mechanism28,48-50 but because a sophisticated 3D human 
in vitro drug testing model may provide a non-live animal 
means to “fast-track” re-purposed drugs to clinic for GBM 
treatment. Indeed, CLM has already been demonstrated, 
some evidence of good tolerance and efficacy in small/an-
ecdotal patient cohorts with 80.8% of patients from a co-
hort of 27 showing good partial response both clinically and 
radiologically.51
In our studies, GBM and MG co-cultures were established 
at a ratio from 10% to 50% of MG in culture to mimic the 
in vivo levels of MG and, possibly, to correlate the level of 
MG with the malignancy of GBM. All ratios of GBM to MG 
demonstrated that both cell types grow in close contact and 
remain viable (>95% viability) for the tested days of co-cul-
ture. Interestingly, the GBM cells growing in close contact 
with MG revealed a modest increase in proliferation (15%-
30% increase within the three GBM cells). Our data con-
firms the previous reports showing the influence of MG in 
GBM.13,15 Fonseca and co-workers, using conditioned media 
from primary mouse MG and in house human GBM cell line 
reported influence of MG in tumor proliferation (~2-fold in-
crease in MG conditioned media condition).13 Additionally, 
Zhai et al  15 also described that the growth rate of mouse 
GL261 GBM is modestly higher when co-cultured with 
primary mouse MG (15.3% increase). Although both stud-
ies highlight the influence of MG, it is relevant to consider 
that these studies describe mouse cells, while our studies are 
focused on human cells cultured in human-derived serum. 
Based on these data, we further considered the influence of 
MG in the migration of GBM. Three GBM cells revealed a 
greater migration when in culture with MG, as previously 
reported in mouse cell cultures.12 When challenged with cy-
totoxic agents, GBM cells showed an increase in prolifera-
tion when in contact with MG. Our studies show that even 
a low amount of MG (10%-20%) is able to confer resistance 
of GBM to cytotoxics. Little is known regarding the role of 
non-neoplastic cells, particularly, MG in resistance of GBM. 
Previous studies.52,53 have described that astrocytes induce 
drug resistance. Using a panel of human GBM cells constitu-
tively expressing a fusion transgene encoding luciferase and 
the enhanced green fluorescence protein (eGFP), co-cultures 
of eGFP/Luciferase GBM, and astrocytes were explored as a 
model for drug screening.53 Experiments demonstrated that 
the presence of astrocytes mediated a significantly higher 
cell survival after TMZ treatment in U251, C6, and A172 
GBM cell lines and also doxorubicin treatment in certain cell 
lines (U251 and LN-18). In a subsequent study, a co-culture 
was established using human astrocytes and GBM cells to 
comprehend the protective mechanisms of astrocytes.52 In 
response to TMZ and VCR, astrocytes were able to reduce 
glioma cell apoptosis induced by these drugs owing to the 
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direct contact between astrocytes and glioma, mainly, medi-
ated through connexion 43 gap junctions.52 Recently, using a 
3D matrix comprised of oligomer type-I collagen and hyal-
uronan, Herrera-Perez and co-workers established cultures of 
patient-derived GBM cells with human astrocytes and endo-
thelial precursors in 3D.54 Migration analysis of GBM cells 
within the 3D in vitro model demonstrated that the presence 
of astrocytes significantly increases the migration of GBM, 
while presence of endothelial precursors has varied effects 
on the migration of different GBM cell lines. Although the 
influence of astrocytes in GBM drug resistance is becoming 
clear, we unrevealed the unknown role of MG in a range of 
human GBM cell lines suggesting the relevance of the in-
corporation of MG cells in novel in vitro models for drug 
screening.
Based on our results showing the protective effect of 
MG on GBM, we established the 3D in vitro model com-
prising the co-culture of GBM and MG in a hyaluronic ac-
id-based hydrogel for drug screening. As observed in the 
2D experiments, MG cells influenced GBM growth and, 
specially, in the 3D ECM a greater proliferation rate was 
obtained in the co-culture in comparison to monoculture 
of GBM. Using this in vitro 3D model, drug resistance to 
CLM and VCR was shown to be attenuated by the presence 
of MG cells in a greater extent than the resistance observed 
in 2D culture conditions. Bioengineered hydrogels with 
brain-mimicking biochemical and mechanical properties 
have been described for 3D in vitro models of GBM.36,55,56 
In particular, hyaluronic acid-based hydrogels have been 
shown to support GBM cells (U-87 MG) maintaining them 
viable, active, and responsive to matrix-immobilized hy-
aluronic acid leading to the upregulation of genes associ-
ated with matrix remodeling and tumor growth.36,55,57 Few 
studies, however, have explored the culture of GBM with 
non-neoplastic cells in a 3D condition for assessment of 
drug response. Using a 3D matrix of collagen-hyaluronan, 
patient-derived GBM cells in co-culture with astrocytes 
and endothelial cells treated with SH-4-54 (small molecule 
signal transducer and activator of transcription, STAT3, 
inhibitor) showed a ~100% survival, while 80% and 38% 
survival was obtained with 3D ECM with no stromal cells 
and 2D monolayers, respectively.54
Here, we investigated the influence of the in vitro tumor 
microenvironment comprised of 3D matrix and non-neo-
plastic cells (MG) on the growth, proliferation, and resis-
tance to cytotoxic drugs of various human GBM cell lines. 
Our results confirm the role of MG in GBM behavior using 
human cell lines cultured in human serum-based conditions 
and validate the use of in vitro controllable platforms that re-
capitulate the microenvironment of GBM as powerful tools 
for cancer studies. This work represents the first in a series 
which are planned to report on the systematic development 
of 3D human models of brain/GBM microenvironment for 
preclinical testing of therapeutics, providing a non-labo-
ratory animal approach to better reflect the unique condi-
tions inherent within the human brain. Our studies in both 
2D and 3D concerning the influence of MG on GBM drug 
sensitivity, which are reported herein will be further es-
tablished to test the role of non-neoplastic astrocytes, as 
well as, pericytes and hyperplastic endothelial cells ob-
tained from biopsies from GBM glomerular microvascular 
proliferation/endothelial hyperplasia regions. Moreover, 
since stem cell phenotypes are present in patient xenograft 
models,58 GBM cell populations reflecting standard and 
stem cell phenotypes will be used in our ultimate human 
3D preclinical drug-testing models. We are also planning 
on exploring human patient-derived, induced pluripotent 
stem cells (iPSCs), which have been reported to show great 
promise in engineering models,59 and can provide a more 
realistic representation of human disease and treatment re-
sponse than the established cell culture and animal models. 
Moreover, within these human iPSC-based 3D preclinical 
testing models, we can use gene silencing approaches of 
key genes that regulate the pathways of therapeutic sen-
sitivity and resistance. Indeed, such approaches have al-
ready been utilized in in vitro organoids of a few different 
cancers for elucidation of regulators of tumorigenesis and 
therapeutic sensitivity.60 The information within this paper 
therefore paves the way for a new era heralding improve-
ment in the preclinical testing of therapeutics for malignant 
brain tumors using manipulated, 3D human in vitro models 
which better represent a clinical situation than existing lab-
oratory animal models which have hitherto be designated 
as “gold standards.”
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